Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals reported a net loss of $3.2 million, or $0.46 per share, for the first quarter of 2026, compared to a net loss of $6.4 million, or $2.61 per share, in the same period last year. The company's cash and cash equivalents increased to $22.2 million as of March 31, 2026, from $14.4 million as of December 31, 2025. Reviva has filed a provisional patent application for a new form of brilaroxazine, aiming to extend patent life and commercial exclusivity through 2046. The company expects FDA feedback on this strategy in mid-2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.